Identity and Access Management Market Set for Significant Growth Driven by Cybersecurity Needs

According to the latest market research study published by P&S Intelligence, the global identity and access management (IAM) market is projected to witness substantial growth, reaching USD 66.31 billion by 2032, growing at a robust CAGR of 15.20% from USD 21.56 billion in 2024.

This growth is driven by the increasing need for organizations to secure sensitive information and ensure smooth, authorized access across digital platforms. The market is experiencing a significant shift due to the rising threat of cyberattacks and data breaches, pushing organizations to adopt IAM solutions to meet compliance requirements and safeguard against unauthorized access. Technological innovations such as zero-trust models, AI integration, and self-sovereign identities are transforming the IAM landscape, making these solutions more efficient and cost-effective. Additionally, the growing adoption of enterprise mobility and the shift toward cloud-based environments are fueling the demand for IAM solutions across industries.

Key Insights

The IAM market is categorized into solutions and services, with the solution segment leading the market due to its ability to secure organizations’ digital infrastructure and platforms. The service segment, however, is growing at a faster pace, driven by increased demand for specialized IT services, including integration, consulting, and maintenance.

The demand for IAM solutions is being particularly driven by heightened digital security concerns, including identity theft and data breaches, which are increasing the need for comprehensive identity management systems. The global cybersecurity spend is projected to grow from USD 206.8 billion in 2024 to USD 352.5 billion by 2032.

In terms of deployment models, on-premises IAM solutions dominate the market, holding a 55% revenue share. However, cloud-based IAM solutions are seeing rapid growth due to their scalability and cost efficiency, with hybrid deployments becoming increasingly popular.

North America remains the largest market for IAM solutions, owing to high investments in cybersecurity, whereas the Asia-Pacific region is emerging as the fastest-growing market due to rapid digital transformation and increasing cybersecurity threats.

The market faces challenges, including the high cost of IAM system implementation and the complexities of integration with existing IT infrastructure. Additionally, concerns around data privacy and compliance with regulations such as GDPR and HIPAA are limiting the widespread adoption of IAM solutions, particularly among small to medium-sized enterprises.

The integration of AI and machine learning into IAM solutions is enhancing security measures, automating user provisioning, and improving threat detection. Furthermore, innovations in self-sovereign identity solutions are enabling individuals to control their data independently, providing stronger security and reducing reliance on physical documentation.

The rise of BYOD (Bring Your Own Device) policies is complicating IAM management, creating new challenges in maintaining consistent security protocols across diverse devices and platforms, and expanding potential attack surfaces.

Key players in the IAM market are focusing on expanding their product portfolios, developing innovative solutions, and forming strategic partnerships to capture a larger market share. These efforts are further propelling the market’s growth and driving the adoption of IAM solutions across industries such as BFSI, healthcare, and public sector organizations.

Biosimilars Industry Growth, Development and Future Analysis

Biosimilars Market

A number of factors such as the increasing incidence of chronic diseases, rising investments in research and development (R&D) initiatives by biopharmaceutical companies, and growing geriatric population will drive the biosimilars market at a robust CAGR, of 29.6%, during the forecast period (2019–2024). Moreover, lower price of biosimilars than reference drugs and presence of an extensive pipeline of these biological products will also catalyze the market growth. The market revenue stood at $6.0 billion in 2018 and it is projected to reach $26.7 billion by 2024.

One of the prime factors contributing to the market growth is the surging incidence of chronic diseases, such as cardiovascular diseases (CVDs) and cancer. According to the World Health Organization (WHO), 2.26 million, 2.21 million, 1.93 million, 1.41 million, 1.20 million, and 1.09 million new cases of breast cancer, lung cancer, colon and rectum cancer, prostate cancer, skin (non-melanoma) cancer, and stomach cancer, respectively, will be recorded across the world in 2020. The WHO also estimates that approximately 17.9 million global deaths occur due to CVDs annually.

At present, companies operating in the biosimilars market are engaging in product launches to march ahead in the competition. For instance, in 2018, adalimumab was launched in the European market by Samsung Bioepis, Sandoz International GmbH, Mylan N.V., and Amgen Inc. These companies aim to launch this product in the U.S. market by 2023. Additionally, the market players are also focusing on partnerships and collaborations to consolidate their position. For example, in June 2018, Biocon India Private Limited collaborated with Sandoz International GmbH to develop, manufacture, and market next-generation biosimilars, such as Etanercept.

The product segment of the biosimilars market is classified into recombinant glycosylated proteins, recombinant non-glycosylated proteins, and recombinant peptides. Under this segment, the recombinant glycosylated proteins category generated the highest revenue in 2018, due to the less complexity, high stability, and smooth approval process of such biosimilars. This category is further classified into follitropin, monoclonal antibodies (mAbs), and erythropoietin (EPO). Among these, the mAbs category is expected to hold the largest market share in coming years, due to the surging usage of such biosimilars in treating cancer and diabetes.

Furthermore, the categories under the indication segment of the biosimilars market include rheumatology, oncology, infectious diseases, chronic diseases, auto-immune diseases, blood-related disorders, growth hormone deficiency (GHD), and others. Under this segment, the oncology category accounted for the largest market share in 2018, owing to the soaring cases of cancer worldwide. As per the WHO, cancer will cause approximately 10 million global deaths in 2020. The organization further estimates that lung cancer, colon and rectum cancer, and liver cancer will be the leading causes of death worldwide, accounting for 1.80 million, 935,000, and 830,000 deaths, respectively, in 2020.

According to P&S Intelligence, the European biosimilars market generated the highest revenue in 2018, due to the burgeoning aging population and mounting investments being made by the biopharmaceutical companies in R&D activities. For instance, the WHO forecasts that the number of individuals aged 85 years and over in Europe will rise from 19 million in 2020 to 40 million by 2050. Besides, the presence of a flexible regulatory framework will also fuel the demand for biosimilars in the region.

Therefore, the soaring cases of cancer and CVDs will facilitate the demand for biosimilars in the forthcoming years.

Ciao mondo!

Benvenuto in Libero Sito. Questo è un articolo di esempio per il tuo nuovo sito: puoi modificarlo o eliminarlo, aggiungere altri articoli e pagine per costruire al meglio il tuo Libero Sito